A chemical biology approach to identifying cyclic peptide antibiotics

南安普顿大学将专注于将SICLOPPS技术应用于抗菌和抗真菌目标，最初的重点是大肠杆菌。默克和南安普顿大学将在细胞类型和表型读出方面达成一致，以支持这一战略。南安普顿大学随后将把SICLOPPS技术应用于预先讨论的细胞类型，并检查感兴趣的表型结果。数据解释、随后的生物靶点鉴定和肽合成/优化将在南安普顿大学进行。如果合适，默克将提供多肽合成支持。默克将对南安普顿大学鉴定的肽进行适当的细胞检测或无细胞检测，并提供适当的化学生物学支持，因为它与生物靶标反褶积有关。最低限度来说，成功被定义为鉴定出新的多肽化学物质，对感兴趣的细菌具有适度的体外抗菌活性。

University of Southampton will focus on applying the SICLOPPS technology to antibacterial and antifungal targets, with initial focus on E. coli. Merck and University of Southampton will agree upon cell type(s) and phenotypic read-out(s) of interest to support this strategy. University of Southampton will then apply SICLOPPS technology to pre-discussed cell-types and examine results for phenotype(s) of interest. Data interpretation, subsequent biological target identification, and peptide synthesis/optimization will be performed at University of Southampton. If appropriate, Merck will provide peptide synthesis support.Merck will test resulting peptides identified by University of Southampton in appropriate cell-based assays or cell-free assays and provide appropriate chemical biology support as it relates to biological target deconvolution. Minimally, success is defined as identification of new peptidic chemical matter with modest in vitro antimicrobial activity against the bacteria of interest.